No connection

Search Results

FONR vs SEER

FONR
FONAR Corporation
NEUTRAL
Price
$18.61
Market Cap
$117.3M
Sector
Healthcare
AI Confidence
75%
SEER
Seer, Inc.
BEARISH
Price
$2.00
Market Cap
$112.8M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
FONR
16.18
SEER
--
Forward P/E
FONR
--
SEER
-1.9
P/B Ratio
FONR
0.69
SEER
0.43
P/S Ratio
FONR
1.11
SEER
6.81
EV/EBITDA
FONR
6.29
SEER
0.69

Profitability

Gross Margin
FONR
40.8%
SEER
51.06%
Operating Margin
FONR
11.74%
SEER
-413.83%
Profit Margin
FONR
7.12%
SEER
0.0%
ROE
FONR
6.01%
SEER
-25.08%
ROA
FONR
3.16%
SEER
-14.71%

Growth

Revenue Growth
FONR
2.4%
SEER
5.0%
Earnings Growth
FONR
1.1%
SEER
--

Financial Health

Debt/Equity
FONR
0.24
SEER
0.09
Current Ratio
FONR
10.0
SEER
12.84
Quick Ratio
FONR
9.66
SEER
12.23

Dividends

Dividend Yield
FONR
--
SEER
--
Payout Ratio
FONR
0.0%
SEER
0.0%

AI Verdict

FONR NEUTRAL

FONR presents as a classic value play with a stable Piotroski F-Score of 4/9 and a current price ($18.61) trading significantly below its Graham Number ($26.43). The company maintains an exceptionally strong balance sheet with a Current Ratio of 10.00 and very low debt (D/E 0.24), providing a massive safety cushion. However, this financial stability is offset by stagnant growth metrics, with YoY earnings growth of only 1.10%, and a bearish technical trend (10/100). Ultimately, the stock appears to be a low-risk, low-reward 'value trap' unless a growth catalyst emerges.

Strengths
Exceptional liquidity with a Current Ratio of 10.00
Very low leverage (Debt/Equity of 0.24)
Trading at a discount to book value (P/B 0.69)
Risks
Stagnant growth (Revenue growth of only 2.40% YoY)
Bearish technical trend (10/100 score)
Low insider sentiment (40/100)
SEER BEARISH

SEER exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating poor financial health and operational deterioration. Despite a strong current ratio suggesting a remaining cash runway, the company suffers from an abysmal operating margin of -413.83% and stagnant revenue growth of 5%. The long-term price trajectory is catastrophic (-96% over 5 years), and recent insider selling by the CEO and President further signals a lack of confidence in a near-term turnaround.

Strengths
High liquidity with a current ratio of 12.84
Very low debt-to-equity ratio (0.09)
Positive gross margin (51.06%)
Risks
Extreme operational inefficiency (Operating Margin -413.83%)
Critical Piotroski F-Score (1/9) indicating systemic financial weakness
Stagnant revenue growth (5% YoY) for a biotechnology firm

Compare Another Pair

FONR vs SEER: Head-to-Head Comparison

This page compares FONAR Corporation (FONR) and Seer, Inc. (SEER) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile